



Hippo Pathway in Cancer, towards Realization of the Hippo-Targeted Therapy

Guest Editor:

Prof. Dr. Yutaka Hata

Department of Medical
Biochemistry, Graduate School of
Medicine Institute of Science
Tokyo, Tokyo 113-8510, Japan

Deadline for manuscript
submissions:

closed (28 February 2018)

Message from the Guest Editor

Dear Colleagues,

The Hippo pathway is the newest and possibly be the last addition to signalling pathways, which have ever been growing. We know now that the fundamental role of the pathway is the negative regulation of two transcription regulators, YAP1 and TAZ. YAP1/TAZ co-operate with TEAD and other transcription factors to regulate cell proliferation and differentiation.

Human cancers are frequently associated with deregulation of the Hippo pathway. The consequent hyperactivation of YAP1/TAZ and TEAD induces epithelial-mesenchymal transition and enhances drug resistance. Accordingly, the incidence of metastasis and recurrence is increased. It is reasonable to assume that inhibition of YAP1/TAZ and TEAD improves prognosis in cancer patients. This Special Issue will highlight a part of the efforts of researchers towards the realization of Hippo-targeted therapy and provide a forum for brainstorming.

Prof. Yutaka Hata
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)